PET scans show biomarkers could spare some breast cancer patients from chemotherapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A study using PET scans has identified a biomarker that may accurately predict which patients with one type of HER2-positive breast cancer might best benefit from standalone HER2-targeted agents, without the need for standard chemotherapy, according to a study led by researchers at the Johns Hopkins Kimmel Cancer Center.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Technological innovations are often hailed as transformative tools capable of revolutionizing healthcare. From gene editing for conditions like sickle cell disease to AI predicting hospital readmissions, to telemedicine expanding healthcare access, these advancements have the potential to change the way we treat diseases. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login